Dr. Ali A. Damavandy, MD

Dr. Damavandy practices at District Dermatology in Mclean, Virginia.

Dr. Damavandy's NPI, 1376836668, was assigned on May 19, 2011. Dr. Damavandy graduated from George Washington University School of Medicine and Health Sciences in 2011. Dr. Damavandy holds Virginia license 0101260257.

Dr. Damavandy's primary practice is District Dermatology, at 6711 Whittier Ave Ste 101 Suite 101, Mclean, VA 22101. The practice phone is (703) 992-9211.

Dr. Damavandy's primary practice is District Dermatology in Mclean, Virginia. The medical group on file is District Dermatology. Dmand AI also links Dr. Damavandy to 1 more physician office, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Damavandy practices, 2 sites in all. Vendor and product names are available with a free account.

Mohs-micrographic surgery is Dr. Damavandy's primary specialty in the NPI Registry, under taxonomy code 207ND0101X. Dr. Damavandy is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Damavandy's licenses on file in 5 states: Virginia, Maryland, Pennsylvania, Delaware and District of Columbia.

Dmand AI lists acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, cold sores or genital herpes, contact dermatitis, hives, itchy rashes and psoriasis among the conditions Dr. Damavandy treats.

CMS data shows 2,768 Medicare services from Dr. Damavandy across 29 procedure codes in 2024, for 523 Medicare patients. Medicare paid $496,792 for them. Every service was in an office.

CMS counts 523 Medicare patients who saw Dr. Damavandy in 2024. The largest group is 75 to 84, with 255 patients. 75% of them have high cholesterol, and 62% have high blood pressure. Their average risk score is 0.97, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Damavandy's median patient age at 65, with 44% women.

In 2024, Dr. Damavandy wrote 513 Medicare Part D claims for 252 patients. 97% of them were for generic drugs. CMS names the drug for 404 of them, across 9 drugs with 11 or more claims each, at $6,623 in total drug cost. In 2023, CMS named 296 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Damavandy for performance year 2024, reported as part of a group. Dr. Damavandy accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 136 procedures of melanoma (skin cancer) excision by Dr. Damavandy, more than 95% of the clinicians it reports for that procedure.

Removal of nail tissue: 1 to 10 procedures (CMS shows small counts as a range)

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 6 papers to Dr. Damavandy, published from 2007 to 2015. 2007 was the busiest year, with 2. The most frequent topics are Immunohistochemistry, Skin Neoplasms and Thymosin. Dr. Damavandy has published most often in Ann N Y Acad Sci. Dr. Damavandy's most frequent co-authors are Arash Radfar, MD, David G. Brodland, MD and Mark A. Cappel, MD.

CMS Open Payments shows 43 general payments to Dr. Damavandy from 14 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 99% of the total. Abbvie Inc. paid the most, $616.

Dmand AI lists 1 award for Dr. Damavandy, most recently AOA Inductee 2011 in 2011.

Dr. Damavandy graduated from George Washington University School of Medicine and Health Sciences in 2011. Dr. Damavandy is a member of AOA.

Dr. Damavandy is in network with 17 carriers, including Aetna, Humana and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.